Rocatinlimab’s OX40-targeted therapy for severe atopic dermatitis: systemic gaps in clinical trial design and equity in treatment access

Indigenous and traditional healing systems view atopic dermatitis as a symptom of deeper imbalances—environmental, spiritual, or dietary—rather than a localized immune dysfunction. These systems emphasize prevention through land stewardship, seasonal diets, and community-based care, contrasting with Rocatinlimab’s reactive, pharmaceutical approach. However, their integration into clinical practice is hindered by the dominance of Western biomedical models and the lack of funding for comparative efficacy studies.

The trial’s framing echoes historical patterns where marginalized groups were excluded from or exploited in medical research, such as the Tuskegee Syphilis Study or Henrietta Lacks’ case. Dermatology’s history is marred by racial biases, including the misclassification of Black skin conditions as 'less severe' due to flawed diagnostic tools. The focus on biologics also mirrors past pharmaceutical industry strategies to medicalize social problems (e.g., the opioid crisis) without addressing root causes.

Cross-culturally, atopic dermatitis is often linked to environmental factors like air pollution, pesticide exposure, or urbanization, which are rarely addressed in Western trials. In Japan, 'atopy-prone' individuals are often advised to consume fermented foods (e.g., miso) to modulate immune responses, a practice absent in Rocatinlimab’s trial design. Middle Eastern communities use honey and olive oil topically, with studies suggesting anti-inflammatory benefits, yet these are not considered in efficacy metrics.

The trial’s reliance on placebo-controlled designs and 'rescue therapy' endpoints may underestimate Rocatinlimab’s long-term benefits, as patients often require combination therapies. The OX40 pathway is a valid target, but the study’s binary classification of 'responders' vs. 'non-responders' oversimplifies the heterogeneity of atopic dermatitis. Additionally, the lack of biomarker stratification (e.g., by race or microbiome composition) limits generalizability to diverse populations.

Artistic and spiritual traditions often frame skin conditions as manifestations of suppressed emotions or spiritual disharmony, offering alternative pathways for healing. In many cultures, eczema is associated with 'blocked energy' or ancestral trauma, addressed through rituals, meditation, or community support. These perspectives are absent in Rocatinlimab’s clinical framework, which reduces healing to a biochemical process.

Future models should prioritize patient-centered outcomes, such as quality-of-life metrics and long-term remission, over short-term efficacy. Scenario planning must account for climate change’s role in exacerbating atopic dermatitis (e.g., increased pollen, air pollution) and the need for sustainable, low-cost therapies. Additionally, decentralized clinical trials using digital health tools could improve access for marginalized groups, but require systemic investment in telemedicine infrastructure.

Black and Latino patients are underrepresented in atopic dermatitis trials despite higher prevalence and severity, reflecting systemic biases in recruitment and diagnosis. Low-income communities face barriers to accessing biologics due to cost and insurance denials, yet their lived experiences with alternative therapies are excluded from clinical guidelines. The trial’s design also overlooks the intersectional impacts of racism, poverty, and environmental exposure on disease progression.